Document is current
Any future updates will be listed below
-
Authors
Bestvina, Christine M.
Kim, Chul
Daaboul, Nathalie
-
Funding
Funding for this research was provided by:
EMD Serono (https://doi.org/10.13039/100004755)
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 1 April 2025
First Online: 22 May 2025
Declarations
:
: Christine Bestvina: Advisory Boards/Consulting: Amgen, AstraZeneca, BMS, Daiichi, EMD Serono, Gilead, Guardant, J & J, Mirati, Novocure, Sanofi, Tempus, Turning Point Therapeutics; Travel: BMS, Guardant, J & J; Research Funding to the Institution: AstraZeneca, BMS. Chul Kim: Advisory Boards/Consulting: Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J & J, Pinetree, Boehringer Ingelheim, Gencurix, Bayer; Research funding (to institution): AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond Therapeutics, ORIC Pharmaceuticals. Nathalie Daaboul: Advisory Boards/Consulting: AbbVie, Amgen, AstraZeneca, BMS, EMD Serono, GSK, J & J, Merck & Co, Kenilworth, NJ, Pfizer, Roche; Research funding to institution: AbbVie, AstraZeneca, Merck & Co, Kenilworth, NJ, Pfizer.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
